NEoadjuvant Gefitinib fOllowed by Surgery and gefiTinib In unresectAble sTage III NSCLC With EGFR Mutations.
NCT02347839
·
clinicaltrials.gov ↗
PHASE2
Phase
WITHDRAWN
Status
OTHER
Sponsor class
Stopped
Slow accrual
Conditions
Lung Cancer
Interventions
PROCEDURE:
Gefitinib-surgery-gefitinib
Sponsor
Sun Yat-sen University